Physicians with University of Minnesota Health Cancer Care are known for their innovative and groundbreaking care for patients with rare cancers, like appendix cancer. Many treatments that are now available to patients around the world were pioneered at our NCI-designated research center: Masonic Cancer Center, University of Minnesota.
The treatment options for patients with appendix cancer are often limited. In recent years, surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat patients with advanced appendix cancer.
Surgical oncologists and Colon and Rectal surgeons with University of Minnesota Health Cancer Care are leaders in HIPEC treatment. Started in 2002, we were the first program in the upper Midwest to start using HIPEC treatment and continue to be a regional leader in this advanced treatment.
In addition to our leadership in providing care, our team is active in research projects through Masonic Cancer Center studying the potential causes and risk factors of appendix cancer and have published their findings in a variety of high-profile medical journals.